ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Weightloss in Menopause

Susan Brian

The Deadly Paradox: Current Practice, Driven by Guidelines, Is Not A…

Michael Makover

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Vitamin D Deficiency

Keck School of Medicine of USC

V. Gevorgyan

ACC 2024 Insights: A Plant-Based Diet

ACC 2024 Insights

N. Barnard

Exercise, Weight Loss, and Breast Cancer Risk: The Importance of BMI

Cleveland Clinic Taussig Cancer Institute

A. Guthrie

SGLT2 Inhibition in 2024: Use in Heart Failure and Mechanism of Acti…

28th Annual Heart Failure 2024: An Update on Therapy

M. Packer

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Houston Methodist

T. R. Mccarty

Obesity and Heart Health: Weighing the Facts

The North American Thrombosis Forum (NATF)

K. D. Palmer Emrich

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Panel Discussion: Hypertension Management and Coronary Calcium Scori…

Scripps Health

D. Cork, C. Mende, A. Robinson

Semaglutide: Where Are We Now and Where Are We Going?

McMaster University Department of Medicine

S. Boushahri, D. Lazzam, K. MacEachern

How to Prescribe Anti Obesity Medications

Beverly Tchang

An Introduction to Tirzepatide for Weightloss

Susan Brian

FLOW Trial Results: GLPs, the Kidneys, and Even More to Come!!

Robert Busch

Diabetes Burden in Metabolic Syndrome and Obesity

Baylor College of Medicine

E. Trofimovsky

Physical Activity and Cardiorespiratory Fitness as Modulators of Hea…

Barry A. Franklin